Last-Resort CAR-T therapy made available for desperate patients
NCT ID NCT03601442
First seen Jan 04, 2026 · Last updated May 06, 2026 · Updated 21 times
Summary
This program provides access to a cancer treatment called tisagenlecleucel (Kymriah) for people with lymphoma, leukemia, or other conditions where standard treatments have failed. It is for patients who cannot join a clinical trial and have no other good options. The goal is to offer a potential benefit when the risks are considered acceptable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.